News for Biotricity, Inc. (BTCY)

Release Date: February 20, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity I

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NBTCY.PK - Biotricity IncQ3 2025 Biotricity Inc Earnings CallFeb 20, 2025 / 10:30PM GMT =======

Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million ”“ an 11% increase sequentially from the imme

**media[542371]**

PR NewswireREDWOOD CITY, Calif. and BELFAST, Northern Ireland, Jan. 15, 2025 REDWOOD CITY, Calif. and BELFAST, Northern Ireland, Jan. 15, 2025 /PRNewswire/

SWK Holdings updates on recent financial activities

PR NewswireREDWOOD CITY, Calif., Dec. 27, 2024 Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without a

PR NewswireREDWOOD CITY, Calif., Dec. 3, 2024 First Time in the Company's HistoryREDWOOD CITY, Calif., Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:

Release Date: November 15, 2024For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity I

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NBTCY.PK - Biotricity IncQ2 2025 Biotricity Inc Earnings CallNov 15, 2024 / 09:30PM GMT =======

Call Start: 16:30 January 1, 0000 4:51 PM ETBiotricity, Inc. (OTC:BTCY)Q2 2025 Earnings Conference CallNovember 15, 2024, 4:30 PM ETCompany ParticipantsDr.

**media[467256]**

Biotricity shareholders elect directors, ratify auditors

Biotricity projects EBITDA positive by end of 2024

Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program

The Global Patient Monitoring Devices Market Size was Valued at USD 48.23 Billion in 2023 and the Worldwide Patient Monitoring Devices Market Size is...

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.

/PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and...